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Available online 29 May 2016HIV-1 positive individuals are at high risk for susceptibility to both pulmonary tuberculosis (TB) and extra-
pulmonary TB, including TB meningitis (TBM) which is an extreme form of TB. The goals of this study are to
determine themechanisms responsible for compromised levels of glutathione (GSH) in the brain tissue samples
derived from HIV-1-infected individuals and individuals with Alzheimer's disease (AD), investigate the possible
underlying mechanisms responsible for GSH deﬁciency in these pathological conditions, and establish a link
between GSH levels and pathophysiology of the disease processes. We demonstrated in the autopsied
human brain tissues that the levels of total and reduced forms of GSH were signiﬁcantly compromised in HIV-
1 infected individuals compared to in healthy subjects and individuals with AD. Brain tissue samples derived
from HIV-1-positive individuals had substantially higher levels of free radicals than that derived from healthy
and AD individuals. Enzymes that are responsible for the de novo synthesis of GSH such as γ-glutamate
cysteine-ligase catalytic subunit (GCLC-rate limiting step enzyme) and glutathione synthetase (GSS-enzyme
involved in the second step reaction) were signiﬁcantly decreased in the brain tissue samples derived from
HIV-1-positive individuals with low CD4+ T-cells (b200 cells/mm3) compared to healthy and AD individuals.
Levels of glutathione reductase (GSR) were also decreased in the brain tissue samples derived from HIV-1
infected individuals. Overall, our ﬁndings demonstrate causes for GSH deﬁciency in the brain tissue from HIV-1
infected individuals explaining the possible reasons for increased susceptibility to the most severe form of
extra-pulmonary TB, TBM.






As of 2010, an estimated 34 million people are living with HIV-1
infectionworldwide,with an additional 2.7million people newly infect-
ed each year. Of those 34 million living with HIV-1, 22.9 million live in
sub-Saharan Africa, a region where Mycobacterium tuberculosis is
endemic [1–4]. One of the hallmarks of acquired immunodeﬁciency
syndrome (AIDS) brought on byHIV-1 infection is increased susceptibil-
ity to opportunistic infections [1–4]. Tuberculosis (TB) is the most
prevalent infectious disease in the world. It is also believed that in de-
veloping countries, as many as 40 to 80% of individuals with AIDS are
at risk of developing TB. In recent years there has been a signiﬁcantMedical Sciences, College of
y of Health Sciences, 309 East
nketaraman).
. This is an open access article underincrease in the incidence of TB due to the emergence of multi-drug
resistant strains ofM. tb and due to increased numbers of highly suscep-
tible immuno-compromised individuals arising from the AIDS pandem-
ic [1–10]. Extra-pulmonary TB has become more common since the
advent of HIV-1 infection and is seen in more than 50% of patients
with concurrent AIDS and TB [5–10]. The risk of extrapulmonary TB
and mycobacteremia increases with advancing immunosuppression
[5–10]. TBM is the most common and severe form of extra-pulmonary
TB and is associated with signiﬁcant morbidity and mortality [5,10].
GSH is critical for a number of cellular functions including protein
synthesis, apoptosis, and transmembrane transport, enzyme catalysis
[11,12]. Establishing proper levels of GSH is also critical for the mainte-
nance and regulation of the thiol-redox state of the cell [13,14,17,18].
GSH is produced de novo from a tripeptide composed of the amino
acids glutamine, cysteine, and glycine. GSH exists intracellularly in
two forms: oxidized form (GSSG) and the reduced form (rGSH).
Formation of rGSH occurs in two-steps synthesis involving twothe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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(GSS). GCL catalysis the ﬁrst step (also the rate limiting step) reaction
involved in the synthesis of GSH and is composed of a catalytic (GCLC)
and a modiﬁer (GCLM) subunit [14,22]. Alternatively, GSSG can be
converted back to GSH in the presence of the enzyme glutathione
reductase (GSR) using cofactor NADPH [14].
We observed in vitro that the virulentM. tb strain is sensitive to GSH
at physiological concentrations (5 mM) [21]. We also found that
enhancing the levels of GSH in human macrophages by treatment
with either N-acetyl cysteine (NAC) or with rGSH formulated in
liposomes (L-GSH) signiﬁcantly reduced the intracellular growth of
M. tb [11]. Thus, GSHhas direct antimycobacterial activity and also func-
tions as an effector molecule in innate defense against M. tb infection
[11,15,16,19,20,21]. We have reported that GSH, in combination with
cytokines such as IL-2 and IL-12, enhances the activity of natural killer
(NK) cells to inhibit M. tb growth inside human monocytes [33]. We
also showed that GSH activates T cell functions to controlM. tb infection
inside human monocytes [16]. Finally, we demonstrated that the total
and reduced forms of GSH were signiﬁcantly compromised in macro-
phages, NK cells, and T cells isolated from the peripheral blood of HIV-
1-infected individuals [15,19,33,16]. Decreased levels of GSH in individ-
uals with HIV-1 infection were accompanied by diminished levels of
enzymes, such as GCLC and GSS in the red blood cells [34]. We also
established that compromised levels of GSH in immune cells derived
from the peripheral blood of individuals with HIV-1 infection led to in-
creased survival of M. tb inside macrophages [15,16,19]. Augmenting
the levels of GSH in macrophages derived from individuals with HIV
infection resulted in improved control of M. tb infection [15,19]. Fur-
thermore, cytokines that are responsible for controlling intracellular
infections such as TNF-α, IL-1β, IL-2, IFN-γ, and IL-12 were found to
be compromised, while IL-10, an immunosuppressive cytokine was
elevated in the plasma samples of HIV-1-infected individuals [20,35].
We have successfully demonstrated that supplementing individuals
with HIV-1 infection (CD4 T cell counts between 200–900/mm3) for
13 weeks orally with L-GSH (supplied by Your Energy Systems) signiﬁ-
cantly increased the levels of cytokines, such as IL-2, IL-12 and IFN-γ,
which are important for mediating effective immune responses against
intracellular infections [20]. L-GSH supplementation in HIV-1-infected
individuals also resulted in a substantial decrease in the levels of free
radicals and immunosuppressive cytokines such as IL-10 and TGF-β,
relative to those in a placebo-controlled cohort [20]. We observed that
the oxidative stress in HIV-1 infection is due to a systemic increase in
IL-6 production triggered by the virus and this is further enhanced by
diminished levels of GSH. Elevations of TGF-β are associated with a
number of factors that may perpetuate immunosuppression in HIV-1
infection [15,35]. Oral L-GSH ingestion was able to decrease TGF-β and
increase GSH levels in the plasma of HIV-1-infected individuals [20].
Our study [20] showed that IL-10, an immunosuppressive cytokine
remains elevated in HIV-1-infected individuals on successful HAART
therapy. L-GSH can lower the level of IL-10 after 13 weeks of oral inges-
tion [20]. Taken together, we showed that L-GSH supplementation to
HIV-1-infected individuals improved their T-helper-1 (TH1) response,
which is associated with enhanced defense against intracellular
infections. Our ﬁndings imply that oxidative stress and redox imbalance
that occur in HIV-1 infection often leads to inappropriate immune re-
sponses and maintaining redox homeostasis result in host-protective
immune responses against intracellular infections [20].
The methylation and transsulfuration pathways are intimately
linked and have been implicated in the progression of neurologic
damage and immune cell depletion caused by HIV-1 infection [26].
Metabolites related to methylation and transsulfuration pathways
include: S-adenosylmethionine (SAMe), homocysteine, cysteine,
cysteinyl-glycine, and GSH [26]. It has been shown in HIV-1-infected
patients that the levels of GSH, SAMe and cysteinyl-glycine, but not
homocysteine or cysteine, were signiﬁcantly reduced in the cerebrospi-
nal ﬂuid (CSF) [26]. Administration of SAMe-butanedisulphonate,800 mg/d intravenously for 14 days, was associated with signiﬁcant
increases in CSF SAMe and GSH [26]. However, conﬂicting results
were obtainedwhen the GSH levels were determined in the brain tissue
lysates from HIV-1-transgenic rats [32].
In this study, we examined the levels of GSH and enzymes involved
in the synthesis of GSH in autopsied human brain tissues of HIV-1-
infected individuals. Disturbances in GSH homeostasis are implicated
in the etiology and/or progression of a number of neurodegenerative
diseases including AD [36,37,38]. GSH deﬁciency or a decrease in the
GSH/GSSG ratio manifests itself largely through an increased suscepti-
bility to oxidative stress, and the resulting damage is thought to be
involved in the pathogenesis of AD [36,37,38]. Since GSH deﬁciency
plays an important role during the onset and progression of AD, we
also wanted to examine the levels of GSH and causes for GSH deﬁciency
in the brain tissues derived from individuals with AD, a neurodegener-
ative condition with increased oxidative stress. Our results suggest an
important mechanism that is responsible for decreased levels of GSH
in the brain tissue samples derived from individuals with HIV-1 infec-
tion which could represent a risk factor for the onset of TBM.
2. Materials and methods
2.1. Subjects
All assays in this study were conducted in human brain tissue sam-
ples (frontal cortex region) obtained from three different groups such
as 1) non-demented healthy group (control) 2) AD patients 3) and
non-demented HIV-1 infected patients (with low and high CD4 T cell
counts). We did not use samples from individuals with co-morbidity
such as HIV + AD. AD and non-demented control cases were obtained
from the University of California-Irvine – ADRC Brain Tissue Repository.
AD cases were age-matched with normal healthy control. The average
ages between the AD and normal control subjects were 86 years old.
Inclusion criteria for AD group required that all subjects had ADwith se-
vere plaques and tangles. The exclusion criteria ruled out any meningi-
tis, trauma to the head, and any viral and bacterial infections in brain
tissues.
The HIV-1 infected cases were obtained from the National
NeuroAIDS Tissue Consortium (NNTC) at U.C. San Diego. The HIV-1
subjects were divided into two groups: HIV-1-positive with CD4+
b200 cells/mm3 and CD4+ N200 cells/mm3 and were labeled as low
and high CD4+, respectively. The average ages for the low CD4+
group were 42 years, and 52 years for high CD4+ group.
2.2. Sample preparation for bioassay measures
Upon receipt, brain tissues (frontal cortex) from AD, non-demented
healthy controls, and non-demented HIV-1 were stored in−80 °C. On
the day of sample preparation, brain tissues from the three experimen-
tal groups were removed from−80 °C and thawed in PBS lysis buffer
(pH 7.4) containing 320 mM sucrose, 1% of 1.0 M Tris-HCl (pH = 8.8),
0.098 mM MgCl2, 0.076 mM EDTA, phosphatase inhibitor cocktail
(Sigma Aldrich, St. Louis, MO). The brain tissues were homogenized by
10 quick pulses using the hand held homogenizer. The homogenates
were centrifuged at 14,000 ×g for 10 min to remove cellular debris.
The supernatantswere separated in order to determine the total protein
concentration using the BCA method (Pierce, Rockford, IL). Additional
extraction was performed with RIPA buffer (50 mM Tris-HCl pH 7.4,
150 mM NaCl, 1% Triton x-100, 1% Sodium deoxycholate, 0.1% SDS,
1 mM EDTA, Protease Inhibitors [Roche]). Brain tissue lysates were
then stored in−80 °C until use.
2.3. Measurement of GSH
Total, oxidized and reduced forms of GSH were measured in the
brain lysates from normal healthy controls, AD, and HIV-1 groups. A
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concentrations of total, oxidized and reduced forms of GSH. All tissue
lysates were deproteinized with 5% Sulfosalicylic acid (SSA) to help
remove any protein thiols present, and slow oxidation of rGSH. The
SSA concentration levels were brought down to 1% by dilution of
assay buffer before analysis. Samples were then assayed for total, free
and oxidized GSH following the manufacturer's protocol. Results were
corrected for protein levels andwere reported in μmoles GSH/g protein.2.4. Measurement of oxidative stress or reactive oxygen species (ROS)
ROS production was determined by measurement of malondial-
dehyde or MDA (end product of lipid peroxidation-an indirect measure
of ROS production) in brain lysates. MDA is a byproduct of lipid peroxi-
dation. Once MDA forms an adduct with thiobarbituric acid (TBARS) at
90 °C− 100 °C, a color change occurswhich can bemeasured colorimet-
rically at 530–540 nm. Baseline levels of MDA were measured in brain
lysates. MDA levels were measured using a TBARS Assay Kit (Cayman
Chemical, 10009055). The assay procedure included with the kit was
followed to obtain MDA sample concentrations. Results were corrected
for protein levels and were reported in μmoles MDA/g protein.2.5. Western blot analysis of GSH synthesis enzymes in brain lysates
Total protein concentration in the brain lysates was measured using
the Coomassie blue colorimetric assay. A total of 35 μg of total brain
lysate proteins per sample were separated by denaturing polyacryl-
amide electrophoresis with 12% polyacrylamide. The membranes were
blocked for one hour at room temperature with Tris buffered saline
containing tween-20 (TBST) and 5% nonfat drymilk, with mild shaking.
The membranes were then incubated overnight with primary antibody
diluted in 5% nonfat dry milk blocking buffer at 4 °C with mild shaking.
Primary antibodies were GCLC (1:1000; Abcam), GSS (1:1000; Abcam),
GSR (1:250; Abcam) and Glyceraldehyde phosphate dehydrogenase
(GAPDH 1:1000; Abcam). Following incubation with primary antibody,
the membranes were washed ﬁve times with TBST for 5 min at room
temperature. The membranes were then incubated at room tempera-
ture for one hour with horseradish peroxidase-conjugated goat anti-
rabbit (Millipore Cat# 12-348) or goat anti-mouse (Millipore Cat #
12-349) secondary antibody diluted with TBST followed by another
set of washing with TBST. Chemiluminescent substrate (Thermo Fisher
Scientiﬁc) was added onto the membrane followed by exposure to the
X-ray ﬁlm. Following this, the X-ray ﬁlm was developed in the dark
room. Resulting immunoblots were captured by Versadoc and
densitometrically analyzed by Image J.2.6. Measurement of cytokines – IL-1 and TNF-α
Cytokine levels were measured using Enzyme-linked Immunosor-
bent Assay (ELISA). The cytokines that were measured in the brain
tissue lysates isolated from the subjects IL-1β and TNF-α (eBioscience
ELISA Ready-Set-Go: IL-1β cat # 88-7010, TNF-α cat # 88-7346). The
cytokine levels were measured following the manufacturer's protocol.2.7. Statistical analysis
Statistical data analysis was performed using Graph Pad Prism Soft-
ware version 6. Levels of total GSH, rGSH, GSH synthesis enzymes, MDA
and cytokines were compared between non-demented healthy
controls, AD, and non-demented HIV-1 with low and high CD4+ T
cell counts group using the unpaired t-test with Welch correction.
Reported values are in means, p b 0.05 was considered signiﬁcant.3. Results
3.1. Assay of GSH in brain lysates
Our analysis of the levels of total and reduced forms of GSH in the
frontal cortex of HIV-1-infected individuals showed a signiﬁcant
decrease compared to healthy and AD individuals (Fig. 1). Total GSH
levels in AD subjects were lower than the healthy controls, however
the decrease was not statistically signiﬁcant (Fig. 1A). Further analysis
of HIV-1-positive individuals showed that subjects with low and high
levels of CD4+ T-cells had signiﬁcantly diminished levels of total and
reduced forms of GSH compared to healthy individuals (Fig. 1A,B).
There was a signiﬁcant and 3-fold decrease in the levels of rGSH in the
brain tissues from HIV-1 subjects compared to AD (Fig. 1B).
3.2. Quantifying the levels of GSH enzymes GCLC, GSS, GSR
Weelucidated the causes for compromised levels of GSH, by demon-
strating by Western blot analysis that the levels of GCLC (catalytic
subunit of the enzyme responsible for catalyzing the ﬁst-step reaction
involved in the GSH synthesis) were signiﬁcantly compromised in AD
and HIV-1 positive individuals with low levels of CD4+ T-cells com-
pared to the healthy group (Fig. 2A,B). Interestingly, the levels of GCLC
were lower from HIV-1 positive subjects with low CD4+ T-cells
compared to AD (Fig. 2A). Levels of GSS (enzyme involved in the second
step of GSH synthesis) were also observed to be signiﬁcantly lower in
AD and HIV-1 positive individuals (both low and high CD4+ T-cell
counts) compared to healthy individuals (Fig. 3A and B). In comparison
to the healthy and HIV-1 groups, the levels of GSR (enzyme that
converts GSSG back to rGSH via NADPH) were signiﬁcantly higher in
AD individuals (Fig. 4A and B). These results indicate that compromised
levels of GSRmay be an additional contributing factor for the decreased
levels of GSH in the brain tissue of individuals with HIV-1 infection.
3.3. Measurement of free radicals in brain lysates
Levels of MDA in brain tissues of AD and HIV-1 groups were
compared to healthy controls.
Lipid peroxidation is a process that is involved in lipid degradation
due to free radical formation. Free radicals are highly reactive and
lead to oxidative damage in cells, including lipids and proteins. Free rad-
icals attack polyunsaturated fatty acids and through the oxidative pro-
cess, MDA, one of the ﬁnal products is formed. Increased production of
MDA is the result of an increase in free radicals found in the cells.
MDA is a commonly used marker for measuring oxidative stress
and in this study, we measured MDA levels in the brain tissues of
healthy, AD, and HIV-1 individuals. Levels of MDAwere comparable be-
tween healthy and AD individuals (Fig. 5). There was a signiﬁcant
increase in the levels of MDA in HIV-1 infected individuals with both
low and high CD4+ T-cell subgroups compared to healthy and AD
groups (Fig. 5).
3.4. Assay of pro-inﬂammatory cytokines IL-1β and TNF-α in brain tissues
We quantiﬁed the levels of pro-inﬂammatory cytokines such as IL-
1β and TNF-α by performing a sandwich ELISA. There was an observ-
able increase in the levels of the pro- inﬂammatory cytokine, IL-1β in
the frontal cortex of HIV-1-positive individuals compared to healthy
andADbrain tissues (Fig. 6A). Previously, our laboratory showed elevat-
ed levels of IL-1β in macrophages of HIV-1 infected individuals
compared to healthy [15]. An important pro-inﬂammatory cytokine
TNF-α, which is responsible for granuloma formation and controlling
M. tb infection inmacrophageswere lower in HIV-1 infected individuals
compared to healthy individuals and individuals with Alzheimer's
disease (Fig. 6B).
Fig. 1.Assay of total GSH and rGSH in brain lysates from healthy, AD, andHIV-1 positive subjects. Frontal cortex specimenwas homogenized and extractedwith PBS buffer. GSH assay was
performed using a colorimetric assay kit from Arbor Assays. Data represent means ± SE from 5 healthy individuals, 5 individuals with AD and 10 HIV-1-positive subjects, *p b 0.05,
**p b 0.05. HIV-1-positive subjects were sub-divided by CD4+ T-cell counts: low CD4+ T-cell b200 cells/mm3 and high CD4+ T-cell N200 cells/mm3. Panel A: total GSH were
signiﬁcantly lower from HIV-1-positive subjects with low CD4+ T-cells and high CD4+ T-cells compared to healthy subjects. Data represents means ± SE from 5 healthy subjects, 5
AD, and 5 HIV-1-positive individuals *p b 0.05, **p b 0.05. No statistical signiﬁcance was shown between healthy and AD patients. Panel B: there was a signiﬁcant decrease in the levels
of rGSH in HIV-1-positive subjects with low CD4+ T-cells and high CD4+ T-cells compared to healthy subjects. Data represents means ± SE from 5 healthy subjects, 5 AD, and 5 HIV-
1-positive individuals *p b 0.05, **p b 0.05.
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GSH is a tripeptide with important immunological functions. GSH
deﬁciency is implicated in the etiology of human pathologies, including
cancer, diseases of aging and neurodegenerative diseases [12]. Our lab-
oratory has previously reported that GSH has direct antimycobacterial
effects and immune-enhancing effects againstM. tb [15,21]. Further-
more, the levels of GSH are diminished in HIV-1 positive individuals
and in individuals with type 2 diabetes [11,15,16,20]. We recently
demonstrated that supplementing HIV-1 positive individuals withFig. 2.Western blot analysis of a GSH de novo synthesis enzyme, GCLC, in brain tissue fromhealt
and B: Western blot results were corrected for GAPDH and reported as relative intensity com
compared to healthy and AD subjects (B; n = 5 healthy, n = 4 AD, n = 5 HIV-1-positive). HI
in the levels of GCLC compared to healthy subjects. No signiﬁcant difference was observed witGSH formulated in liposomes restored the levels of GSH and
cytokines, and improved the immune responses against M. tb
infection [15,20].
In the current study, we demonstrate that the levels of total and
reduced forms GSH are signiﬁcantly compromised in the brain tissue
samples derived from HIV-1 positive individuals (with low and high
CD4+ T-cells) compared to healthy subjects and individuals with AD
(Fig. 1A,B). These results indicate that GSH deﬁciency in the brain tissue
can represent a risk factor for susceptibility to TBM, a severe and fatal
form of extra-pulmonary TB [5].hy subjects, AD andHIV-1-positive subjects. Data representmeans± SE,*p b 0.05. Panels A
pared to GAPDH. Levels of GCLC were signiﬁcantly lower from HIV-1-positive subjects
V-1-positive subjects with low CD4+ T-cells were observed to have signiﬁcant decrease
h HIV-1-positive subjects with high CD4+ T-cells compared to healthy subjects.
Fig. 3.Western blot analysis of GSS, a GSH de novo synthesis enzyme in brain tissues derived from healthy, AD and HIV-1-positive subjects. Data representmeans ± SE,*p b 0.05. Panels A
and B:Western blot results were corrected for GAPDH and reported as relative intensity compared to GAPDH. Compared to healthy subjects, we observed levels of GSS to be signiﬁcantly
lowered from HIV-1-positive subjects with low CD4+ T-cells and high CD4+ T-cells and AD subjects (C; n = 5 healthy, n = 4 AD, n = 5 HIV-1-positive).
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GSS enzymes in the brain tissue lysates of HIV-1 positive individuals
with low CD4+ T cell counts compared to the healthy individuals
(Figs. 2, 3). HIV-1 positive individuals with high CD4+ T cell counts
had a signiﬁcant decrease in the levels of GSS enzyme (but not GCLC)
in their brain tissue lysates (Figs. 2, 3). There was no signiﬁcant
difference in the levels of GCLC and GSS enzymes in HIV-1 positiveFig. 4.Western blot analysis of a recycling enzyme, GSR, in brain lysates from healthy, AD
and HIV-1-positive subjects. Data represent means ± SE,*p b 0.05. Panels A and B:
Western blot results were corrected for GAPDH and reported as relative intensity
compared to GAPDH. We observed a signiﬁcant increase in the levels of GSR in AD
group compared to healthy group. We observed a signiﬁcant decrease in the levels of
GSR from HIV-1-positive subjects with low and high CD4+ T-cells compared to AD
subjects (C; n = 5 healthy, n = 4 AD, n = 5 HIV-1-positive). *p b 0.05, **p b 0.05.
***p b 0.05.individuals between the low and high CD4 T-cell subgroups. In compar-
ison to the healthy group, there was also a signiﬁcant decrease in the
levels of both GCLC and GSS enzymes in the brain tissue lysates from
individuals with AD (Figs. 2, 3). As part of the de novo synthesis, these
two enzymes (GCL and GSS) are critical for maintaining proper balance
between both oxidative and antioxidant forms in the cells [13,15,19].
Furthermore, we also observed a signiﬁcant increase in the levels of
GSR in individuals with AD compared to the healthy group (Fig. 4A,B).
Although there was a decrease in the levels of GSR in HIV-1 infected
individuals with low and high CD4+ T-cells compared to the healthy
group, this decrease was not signiﬁcant (Fig. 4A,B). However, there
was a statistically signiﬁcant decrease in the levels of GSR between AD
group and HIV-1 positive individuals with both low and high CD4+
T-cells (Fig. 4A,B). An increase in the levels of GSR in the brain tissueFig. 5. Assay of MDA in brain tissues from healthy, AD, and HIV-1-positive subjects. MDA
assay was performed using a TBARS kit from Cayman Chemical. Data represent
means ± SE from 5 healthy individuals, 5 AD subjects and 5 HIV-1-positive subjects
*p b 0.05, **p b 0.05. There was a statistical signiﬁcant increase in the levels of MDA in
HIV-1-positive subjects with both low and high CD4+ T-cell counts compared to the
healthy group.
Fig. 6.Assay of IL-1β (panel A) and TNF-α (panel B) in brain tissues fromhealthy, AD, andHIV-1-positive subjects. Data representmeans±SE from5healthy individuals, 5 AD subjects and
5HIV-1-positive subjects *pb 0.05, **p b 0.05. PanelsA and B: assay of IL-1β (panel A) and TNF-α (panel B)wereperformedusing anELISA Ready-Set-Go kit fromeBioscience. Compared to
healthy subjects, HIV-1-positive group was observed to have increased levels of IL-1β compared to healthy subjects. We observed a decrease level of TNF-α in HIV-1-positive subjects
compared to healthy subjects.
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rymechanism to restore the levels of GSH due to compromised levels of
GCLC and GSS enzymes (Figs. 2A, 3A). This compensatory mechanism
explains why there is no notable decrease in the levels of GSH in the
AD group. Our observations demonstrating increased levels of GSR in
the brain tissue lysates from AD group is consistent with the previously
published ﬁndings in Parkinson diseases and other neurodegenerative
diseases demonstrating increased expression of GSR as a compensatory
mechanism to restore the levels of GSH that is being depleted due to
chronic oxidative stress [30,31].
We reported in our previous studies that individuals with HIV-1
infection have increased levels of TGF-β in their plasma and
macrophage supernatants [15,20]. TGF-β is known to block the produc-
tion of GCLC which leads to decreased GSH synthesis [27]. HIV-1
transactivator protein (TAT) has been shown to decrease the amount
of GSH through the modulation of GSH biosynthetic enzymes [28].
TAT also increases free radical production [28]. Therefore, marked
increase in oxidative stress along with increased levels of TGF-β can
diminish the production of enzymes that are involved in the synthesis
of GSH. The master transcription factor nuclear factor (erythroid-de-
rived 2)-like 2 (Nrf2) regulates the expression of antioxidant and
phase II-metabolizing enzymes by activating the antioxidant response
element (ARE) and thereby protects cells and tissues from oxidative
stress [25]. The Nrf2 gene binding to the ARE results in the upregulation
of GSH synthesis enzymes such as GCLC, GCLM, and GSR. New ﬁndings
argue that HIV-1 related proteins downregulate Nrf2 expression and/
or activity, which in turn impairs antioxidant defenses, thereby render-
ing the organs susceptible to oxidative stress and injury [29]. These
studies support our current ﬁndings and elucidate the possible causes
for decreased levels of GSH and diminished expressions of GCLC and
GSS in the brain tissue samples derived from individuals with HIV-1
infection. Inability to induce substantial upregulation of GSR further
explains disruption in the compensatory mechanism in the brain tissue
samples derived from individuals with HIV-1 infection. These novel
ﬁndings add signiﬁcance to our previous ﬁndings that individuals with
HIV-1-infection have low levels of GSH, GCLC and GSS in the red blood
cells isolated from the peripheral blood [34].
We further analyzed the levels of MDA, a byproduct of lipid
peroxidation due to free radical reaction in brain tissue samples from
the three study groups. We observed a signiﬁcant increase in the levels
of free radicals in HIV-1-infected individuals compared to healthy and
AD groups, but there was no signiﬁcant difference between HIV-1
positive individuals with low and high CD4 sub groups (Fig. 5). Based
on our ﬁndings, we conclude that an increased production of free
radicals in HIV-1-infected individuals along with compromised levelsof enzymes required for the synthesis of GSH along with the lack of
GSR increase are mainly responsible for the signiﬁcant decrease in the
levels both total GSH and rGSH (Fig. 1A,B). The brain ismore susceptible
than any other organ in the body to oxidative damage and increased
levels of free radicals alongwith diminished GSHwill reduce the neuro-
protection andmay increase the risk for TBM. Many reports have linked
redox imbalance as a pathogenicmechanism that contributes to AD [12,
23,24]. However, we did not observe any increase in the levels of free
radicals in the brain tissue samples derived from individuals with AD.
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